Literature DB >> 15603370

[Peptic ulcer disease etiology, diagnosis and treatment].

Leokadia Bak-Romaniszyn1, Stanisław Wojtuń, Jerzy Gil, Izabela Płaneta-Małecka.   

Abstract

Authors in this article present etiology, clinical manifestations, diagnostic procedures and treatment of peptic ulcer disease in children and adults. Increased gastric acid output, Helicobacter pylori, NSAIDs and stress are the basic risk factors in peptic ulcer disease. H. pylori infection is a widely known risk factor in peptic ulcer disease and influences diagnostic and treatment procedures. Primary ulcer disease concerns mainly duodenum and is accompanied by H. pylori infection. Gastroscopy and Helicobacter tests are the only reliable procedures to diagnose peptic ulcer disease. Nowadays the most important aim in peptic ulcer treatment is the H. pylori eradication. Therapy with two antibiotics and a protein pomp inhibitor eradicates the bacteria, treats the ulceration and lowers the number of ulcer recurrence. In non-infected H. pylori ulcers or in a long-term treatment protein pomp inhibitors and H2-inhibitors are effective as well in gastroprotective therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15603370

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  2 in total

1.  Trachyspermum ammi (L.) Sprague, superb essential oil and its major components on peptic ulcers: in vivo combined in silico studies.

Authors:  Mahdieh Eftekhari; Afsaneh Hoseinsalari; Mahboubeh Mansourian; Fatemeh Farjadmand; Mohammad Reza Shams Ardekani; Mohammad Sharifzadeh; Gholamreza Hassanzadeh; Mahnaz Khanavi; Mahdi Gholami
Journal:  Daru       Date:  2019-06-19       Impact factor: 3.117

2.  Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI.

Authors:  Peng Wei; Yi-Gang Zhang; Lin Ling; Zi-Qi Tao; Li-Ya Ji; Jie Bai; Bin Zong; Chun-Ying Jiang; Qian Zhang; Qiang Fu; Xiang-Jun Yang
Journal:  Exp Ther Med       Date:  2016-09-09       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.